China Resources Double Crane: Wholly-owned subsidiary Deno Mifepristone Tablets approved for drug supplementary application.

China Resources Double Crane announced that its wholly-owned subsidiary, CR Purple Bamboo, recently received a Notice of Approval for Drug Supplement Application for Dilenoprost tablets issued by the National Medical Products Administration. The drug marketing authorization holder has been changed from "Beijing Jinsai Zeng Medical Technology Co., Ltd." to "CR Purple Bamboo Pharmaceutical Co., Ltd.", while the drug approval number remains unchanged. This drug is used to treat endometriosis, and as of the announcement date, CR Purple Bamboo has accumulated research and development investment of 10.3491 million yuan for this drug. The drug is expected to generate sales revenue of 35.81 million yuan by 2025. This approval will enrich the company's product line and enhance market competitiveness, but drug sales may be affected by various factors and uncertainties.